{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:16Z","timestamp":1791666136977,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970640"],"award-info":[{"award-number":["81970640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370735"],"award-info":[{"award-number":["82370735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02423-1","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:12:56Z","timestamp":1760026376000},"page":"2997-3004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series"],"prefix":"10.1093","volume":"38","author":[{"given":"Qingyun","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"Supplement_2","key":"2423_CR1","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ndt\/gfad067","volume":"38","author":"P Romagnani","year":"2023","unstructured":"Romagnani P, Kitching AR, Leung N et al (2023) The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC). Nephrol Dial Transplant 38(Supplement_2):ii3\u2013ii10","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"2423_CR2","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) Kdigo 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276","journal-title":"Kidney Int"},{"issue":"4","key":"2423_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN (2017) IgA nephropathy. Clin J Am Soc Nephrol 12(4):677\u2013686","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2423_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH et al (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28(4):1306\u20131313","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"2423_CR5","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22):4393\u20134402","journal-title":"Blood"},{"issue":"19","key":"2423_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327(19):1888\u20131898","journal-title":"JAMA"},{"issue":"2","key":"2423_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006609","volume":"13","author":"K Kiryluk","year":"2017","unstructured":"Kiryluk K, Li Y, Moldoveanu Z et al (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13(2):e1006609","journal-title":"PLoS Genet"},{"issue":"7","key":"2423_CR8","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1681\/ASN.2016091043","volume":"28","author":"DP Gale","year":"2017","unstructured":"Gale DP, Molyneux K, Wimbury D et al (2017) Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol 28(7):2158\u20132166","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2423_CR9","volume":"3","author":"P Natale","year":"2020","unstructured":"Natale P, Palmer SC, Ruospo M et al (2020) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 3(3):CD003965","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2423_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.molimm.2011.04.024","volume":"48","author":"NA Daha","year":"2011","unstructured":"Daha NA, Banda NK, Roos A et al (2011) Complement activation by (auto-) antibodies. Mol Immunol 48(14):1656\u20131665","journal-title":"Mol Immunol"},{"issue":"3","key":"2423_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jcla.10071","volume":"17","author":"A Maeda","year":"2003","unstructured":"Maeda A, Gohda T, Funabiki K et al (2003) Significance of serum IgA levels and serum IgA\/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal 17(3):73\u201376","journal-title":"J Clin Lab Anal"},{"key":"2423_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040495","volume":"7","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Koo HM, Lim BJ et al (2012) Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS\u00a0One 7:e40495","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"2423_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN et al (2025) The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol 21(1):9\u201323","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"2423_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nri.2017.67","volume":"17","author":"P Tolar","year":"2017","unstructured":"Tolar P (2017) Cytoskeletal control of B cell responses to antigens. Nat Rev Immunol 17(10):621\u2013634","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"2423_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392(15):1471\u20131483. https:\/\/doi.org\/10.1056\/NEJMoa2410965","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02423-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02423-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02423-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:49Z","timestamp":1777564789000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/9\/2997\/8466186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2423"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02423-1","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest are declared by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of Shanghai Changzheng Hospital (Ethics approval number: CZ9238R). Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}